Home / Intelligence / Webinars / Market Access Opportunities & Challenges: An Exploration of Three Global Trends
Available On Demand
Join Trinity Life Sciences’ Evidence, Value, Access and Pricing and Cell & Gene Therapy experts for a deeper look at the market access trends that will present the most impactful opportunities and challenges for life sciences organizations in 2023.
This webinar will expand upon the trends discussed in the recently released white paper entitled “Global Market Access Trends: 2022 Edition,” focusing on evolving evidence expectations, increasing price transparency regulation and cell & gene therapy expansion.
Key Webinar Topics
- How can life sciences organizations meet evolving evidence expectations in the U.S. and Europe?
- How can the price of pharmaceutical products be successfully negotiated as more stringent price transparency regulation is enforced globally?
- How can organizations keep pace with the evolving cell and gene therapy pricing and reimbursement landscape as this new technology expands?
Featuring
Maximilian Hunt
Partner,
Value, Access & Pricing
Nandini Hadker
Partner,
Evidence Strategy
Ismail Ismailoglu
Associate Principal,
Value, Access & Pricing
Complete the form below to view the on-demand webinar.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.
Related Intelligence
Webinars
Part D in Peril: The Inconvenient Math of IRA Part D Redesign
August 14, 2025 | 12:00 – 12:45 PM ET
Medicare Part D is undergoing its most significant transformation in decades largely driven by the IRA. What does this mean for pharmaceutical manufacturers? Join us for an engaging discussion with Max Hunt, Partner at Trinity, and special guest Dan Simenc, clinical and actuarial expert at Milliman, as they provide perspectives on recent developments and future expectations for Medicare Part D and Medicare Advantage.
Sign Up Now
Blog
Joint Clinical Assessment in the EU: What Life Sciences Companies Need to Know
March 2025 marked a pivotal moment for pharmaceutical and biotech companies operating in the European Union (EU) as the first two molecules began to proceed through the Joint Clinical Assessment (JCA) process. At a recent seminar hosted by Trinity Life Sciences, stakeholders gathered to explore the implications of this new regulatory framework and how to […]
Read More
Blog
Pricing and Access in Germany: Innovation and Strong Evidence Rewarded
Germany’s Medical Research Act (Medizinforschungsgesetz or MFG), which came into force on October 30, 2024, is a major legislative reform aimed at strengthening Germany’s position as an attractive environment for medical innovation and pharmaceutical development. The act provides for confidential negotiated drug pricing, incentives for local clinical trials, simplified clinical trial approvals and harmonization of […]
Read More